Herbert Lepor, MD, discussed NYU Langone's 1,000th focal cryotherapy procedure, Andre De Shields' case, and why prostate cancer treatment is at a turning point.
|Podcasts|January 31, 2022
Oncology Peer Review On-The-Go: Matthew Allaway, DO, on Transperineal Biopsy Approach for Prostate Cancer
Author(s)Matthew Fowler, Matthew Allaway, DO
Matthew Allaway, DO, spoke with CancerNetwork® about a new transperineal biopsy approach to detect cancer in hard-to-reach areas of the prostate.
Advertisement
CancerNetwork® spoke with Matthew Allaway, DO, founder and chief executive officer at Perineologic, about a new prostate cancer biopsy technique that uses a transperineal approach to detect cancer in harder to reach areas of the prostate.
Allaway touched on the American Cancer Society’s annual report, “Cancer Facts & Figures 2022,” which indicated the rate of advanced-stage prostate cancer cases have increased in recent years. He also detailed a companion study to the report, and walked through the specific details and benefits of this biopsy technique.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Reference
Cancer Facts & Figures 2022. American Cancer Society. 2022. Accessed January 28, 2022. https://tinyurl.com/5rdc6nbc
Advertisement
Related to this article
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5